Literature DB >> 16355113

Allele-specific RNA interference for neurological disease.

E Rodriguez-Lebron1, H L Paulson.   

Abstract

Suppressing the expression of toxic genes through RNAi holds great promise for the treatment of human disease. Allele-specific approaches have now been used to silence dominant toxic genes implicated in several neurological disorders. Here, we review strategies used to achieve allele-specific silencing in light of recent developments in the field of RNAi biology. In particular, new insights into siRNA and miRNA processing may be used to improve efficiency and specificity of RNAi therapy. We further discuss steps that can be taken to maximize the therapeutic benefits of this powerful technology. Gene Therapy (2006) 13, 576-581. doi:10.1038/sj.gt.3302702; published online 15 December 2005.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16355113     DOI: 10.1038/sj.gt.3302702

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  38 in total

1.  Two molecular pathways (NMD and ERAD) contribute to a genetic epilepsy associated with the GABA(A) receptor GABRA1 PTC mutation, 975delC, S326fs328X.

Authors:  Jing-Qiong Kang; Wangzhen Shen; Robert L Macdonald
Journal:  J Neurosci       Date:  2009-03-04       Impact factor: 6.167

2.  Allele-specific RNA interference prevents neuropathy in Charcot-Marie-Tooth disease type 2D mouse models.

Authors:  Kathryn H Morelli; Laurie B Griffin; Nettie K Pyne; Lindsay M Wallace; Allison M Fowler; Stephanie N Oprescu; Ryuichi Takase; Na Wei; Rebecca Meyer-Schuman; Dattatreya Mellacheruvu; Jacob O Kitzman; Samuel G Kocen; Timothy J Hines; Emily L Spaulding; James R Lupski; Alexey Nesvizhskii; Pedro Mancias; Ian J Butler; Xiang-Lei Yang; Ya-Ming Hou; Anthony Antonellis; Scott Q Harper; Robert W Burgess
Journal:  J Clin Invest       Date:  2019-12-02       Impact factor: 14.808

3.  Restoration of normal BMP signaling levels and osteogenic differentiation in FOP mesenchymal progenitor cells by mutant allele-specific targeting.

Authors:  J Kaplan; F S Kaplan; E M Shore
Journal:  Gene Ther       Date:  2011-10-20       Impact factor: 5.250

Review 4.  RNA surveillance: molecular approaches in transcript quality control and their implications in clinical diseases.

Authors:  Karen C M Moraes
Journal:  Mol Med       Date:  2009-10-07       Impact factor: 6.354

5.  RNA interference improves myopathic phenotypes in mice over-expressing FSHD region gene 1 (FRG1).

Authors:  Lindsay M Wallace; Sara E Garwick-Coppens; Rossella Tupler; Scott Q Harper
Journal:  Mol Ther       Date:  2011-07-05       Impact factor: 11.454

6.  A novel measurement of allele discrimination for assessment of allele-specific silencing by RNA interference.

Authors:  Masaki Takahashi; Hirohiko Hohjoh
Journal:  Mol Biol Rep       Date:  2014-07-19       Impact factor: 2.316

7.  CRISPR/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington's disease.

Authors:  Su Yang; Renbao Chang; Huiming Yang; Ting Zhao; Yan Hong; Ha Eun Kong; Xiaobo Sun; Zhaohui Qin; Peng Jin; Shihua Li; Xiao-Jiang Li
Journal:  J Clin Invest       Date:  2017-06-19       Impact factor: 14.808

Review 8.  Making sense of nonsense GABA(A) receptor mutations associated with genetic epilepsies.

Authors:  Jing-Qiong Kang; Robert L Macdonald
Journal:  Trends Mol Med       Date:  2009-08-31       Impact factor: 11.951

9.  Allele-specific RNAi mitigates phenotypic progression in a transgenic model of Alzheimer's disease.

Authors:  Edgardo Rodríguez-Lebrón; Cynthia M Gouvion; Steven A Moore; Beverly L Davidson; Henry L Paulson
Journal:  Mol Ther       Date:  2009-06-16       Impact factor: 11.454

10.  Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs.

Authors:  Jiaxin Hu; Masayuki Matsui; Keith T Gagnon; Jacob C Schwartz; Sylvie Gabillet; Khalil Arar; Jun Wu; Ilya Bezprozvanny; David R Corey
Journal:  Nat Biotechnol       Date:  2009-05-03       Impact factor: 54.908

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.